Compare DRTS & IGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DRTS | IGD |
|---|---|---|
| Founded | 2015 | N/A |
| Country | Israel | United States |
| Employees | 125 | N/A |
| Industry | Medical/Dental Instruments | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 546.5M | 460.6M |
| IPO Year | N/A | N/A |
| Metric | DRTS | IGD |
|---|---|---|
| Price | $7.35 | $5.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | 267.7K | ★ 276.9K |
| Earning Date | 03-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.15% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,055.39 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.30 | $5.01 |
| 52 Week High | $8.60 | $6.04 |
| Indicator | DRTS | IGD |
|---|---|---|
| Relative Strength Index (RSI) | 52.69 | 48.52 |
| Support Level | $6.37 | $5.66 |
| Resistance Level | $7.77 | $6.00 |
| Average True Range (ATR) | 0.45 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 68.46 | 50.00 |
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.
Voya Global Equity Dividend and Premium Opportunity Fund are a United States-based diversified, closed-end Fund. The primary objective of the Fund is to seek to provide investors with a high level of income from a portfolio of common stocks with historically attractive dividend yields and premiums from call option writing. The secondary investment objective of the company is capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its managed assets in a portfolio of common stocks of dividend-paying companies located throughout the world.